Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$3.41 -0.6%	$3.34	$2.71 ▼ $4.73	$656.94M	1.23	957,351 shs	1.07 million shs
DAWN Day One Biopharmaceuticals	$6.48 +2.5%	$6.82	$6.08 ▼ $16.76	$640.61M	-1.29	1.13 million shs	1.36 million shs
IOVA Iovance Biotherapeutics	$1.85 -6.6%	$2.41	$1.64 ▼ $12.51	$661.19M	0.86	8.92 million shs	9.06 million shs
IPHA Innate Pharma	$1.80	$2.09	$1.29 ▼ $3.51	$165.92M	0.26	185,813 shs	20,145 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	-0.58%	-4.75%	+5.90%	+1.19%	+11.80%
DAWN Day One Biopharmaceuticals	+2.53%	-2.41%	+3.35%	-21.74%	-52.63%
IOVA Iovance Biotherapeutics	-6.57%	-11.06%	+3.93%	-46.84%	-76.90%
IPHA Innate Pharma	0.00%	-3.23%	-16.47%	-8.40%	-15.89%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABUS Arbutus Biopharma	1.5242 of 5 stars	3.5	0.0	0.0	0.6	2.5	0.6
DAWN Day One Biopharmaceuticals	1.6448 of 5 stars	3.6	0.0	0.0	2.1	2.5	0.0
IOVA Iovance Biotherapeutics	4.6078 of 5 stars	4.3	1.0	4.2	1.7	4.2	1.3
IPHA Innate Pharma	2.8111 of 5 stars	3.8	5.0	0.0	1.3	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	3.00	Buy	$5.50	61.29% Upside
DAWN Day One Biopharmaceuticals	3.13	Buy	$30.57	371.78% Upside
IOVA Iovance Biotherapeutics	2.50	Moderate Buy	$12.22	560.66% Upside
IPHA Innate Pharma	3.50	Strong Buy	$11.00	511.11% Upside

Current Analyst Ratings Breakdown

Latest IPHA, IOVA, ABUS, and DAWN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	IOVA Iovance Biotherapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$17.00 ➝ $2.00
5/12/2025	IOVA Iovance Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $8.00
5/12/2025	IOVA Iovance Biotherapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $10.00
5/12/2025	IOVA Iovance Biotherapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$5.00 ➝ $4.00
5/12/2025	IOVA Iovance Biotherapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/9/2025	IOVA Iovance Biotherapeutics	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/9/2025	IOVA Iovance Biotherapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform
5/9/2025	IOVA Iovance Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $25.00
5/9/2025	IOVA Iovance Biotherapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/9/2025	IOVA Iovance Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $20.00
5/7/2025	DAWN Day One Biopharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$25.00

(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$6.17M	105.85	N/A	N/A	$0.51 per share	6.69
DAWN Day One Biopharmaceuticals	$131.16M	5.01	N/A	N/A	$4.99 per share	1.30
IOVA Iovance Biotherapeutics	$164.07M	3.77	N/A	N/A	$2.33 per share	0.79
IPHA Innate Pharma	$12.62M	13.15	N/A	N/A	$0.11 per share	16.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$69.92M	-$0.41	N/A	N/A	N/A	-1,196.64%	-75.51%	-55.81%	8/7/2025 (Estimated)
DAWN Day One Biopharmaceuticals	-$95.50M	-$0.71	N/A	N/A	N/A	-42.66%	-14.98%	-13.04%	7/8/2025 (Estimated)
IOVA Iovance Biotherapeutics	-$372.18M	-$1.24	N/A	N/A	N/A	-176.49%	-49.71%	-39.18%	8/6/2025 (Estimated)
IPHA Innate Pharma	-$53.53M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest IPHA, IOVA, ABUS, and DAWN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ABUS Arbutus Biopharma	-$0.09	-$0.13	-$0.04	-$0.13	$2.54 million	$1.76 million
5/8/2025	Q1 2025	IOVA Iovance Biotherapeutics	-$0.25	-$0.36	-$0.11	-$0.36	$83.40 million	$49.32 million
5/6/2025	Q1 2025	DAWN Day One Biopharmaceuticals	-$0.46	-$0.35	+$0.11	-$0.35	$30.28 million	$30.76 million
3/27/2025	Q4 2024	ABUS Arbutus Biopharma	-$0.08	-$0.07	+$0.01	-$0.07	$2.20 million	$1.57 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
DAWN Day One Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
IPHA Innate Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	0.04	6.01	6.01
DAWN Day One Biopharmaceuticals	N/A	10.62	10.55
IOVA Iovance Biotherapeutics	N/A	4.18	3.64
IPHA Innate Pharma	2.52	2.60	2.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
DAWN Day One Biopharmaceuticals	87.95%
IOVA Iovance Biotherapeutics	77.03%
IPHA Innate Pharma	0.16%

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	20.30%
DAWN Day One Biopharmaceuticals	6.20%
IOVA Iovance Biotherapeutics	10.30%
IPHA Innate Pharma	31.89%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	191.53 million	152.65 million	Optionable
DAWN Day One Biopharmaceuticals	60	101.36 million	95.08 million	Optionable
IOVA Iovance Biotherapeutics	500	333.93 million	299.54 million	Optionable
IPHA Innate Pharma	220	92.18 million	62.78 million	Not Optionable

IPHA, IOVA, ABUS, and DAWN Headlines

Recent News About These Companies

Innate Pharma (NASDAQ:IPHA) Stock Price Down 1% - Should You Sell?

June 19, 2025 | marketbeat.com

Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences

June 17, 2025 | businesswire.com

Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress

June 13, 2025 | businesswire.com

Innate Pharma S.A. (NASDAQ:IPHA) Short Interest Update

May 30, 2025 | marketbeat.com

Innate Pharma (NASDAQ:IPHA) Shares Down 1.1% - Time to Sell?

May 28, 2025 | marketbeat.com

Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences

May 27, 2025 | businesswire.com

ASCO: Innate claims long-term lymphoma data show 'sustained effect' of anti-KIR3DL2 antibody

May 23, 2025 | fiercebiotech.com

Outcome of Innate Pharma’s 2025 Annual General Meeting

May 23, 2025 | finance.yahoo.com

Outcome of Innate Pharma's 2025 Annual General Meeting

May 23, 2025 | businesswire.com

Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides

May 23, 2025 | businesswire.com

Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting

May 19, 2025 | businesswire.com

Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress

May 15, 2025 | businesswire.com

Innate Pharma S.A. (IPHA) Q1 2025 Earnings Call Transcript

May 13, 2025 | seekingalpha.com

Innate Pharma Reports First Quarter 2025 Business Update and Financial Results

May 13, 2025 | businesswire.com

Innate Pharma announces conference call and webcast for Q1 2025 business update

May 6, 2025 | businesswire.com

Innate Pharma Files Its 2024 Universal Registration Document (Document d'enregistrement universel) and 2024 Annual Report on Form 20-F

April 30, 2025 | businesswire.com

Innate Pharma Unveils Promising Preclinical Data for IPH4502 at AACR 2025

April 29, 2025 | tipranks.com

Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting

April 29, 2025 | businesswire.com

Innate Pharma price target lowered to $11 from $11.50 at H.C. Wainwright

April 25, 2025 | markets.businessinsider.com

Innate Pharma Announces €15M Investment by Sanofi

April 24, 2025 | businesswire.com

Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi's Intention to Make a Strategic Investment in the Company

April 23, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA, IOVA, ABUS, and DAWN Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$3.41 -0.02 (-0.58%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$3.48 +0.07 (+2.02%)

As of 07:00 AM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Day One Biopharmaceuticals NASDAQ:DAWN

$6.48 +0.16 (+2.53%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$6.54 +0.06 (+0.93%)

As of 08:41 AM Eastern

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Iovance Biotherapeutics NASDAQ:IOVA

$1.85 -0.13 (-6.57%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$1.88 +0.03 (+1.62%)

As of 08:47 AM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Innate Pharma NASDAQ:IPHA

$1.80 0.00 (0.00%)

Closing price 06/23/2025 03:59 PM Eastern

Extended Trading

$1.80 +0.00 (+0.28%)

As of 07:21 AM Eastern

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time